Sara M. Tolaney, MD, MPH

Sara M. Tolaney, MD, MPH, concludes the program with advice for community oncologists who are treating patients with breast cancer.

A breast oncologist looks to the future of breast cancer treatment and discusses emerging therapies and ongoing clinical trials.

Expert perspectives on the treatment landscape for triple-negative breast cancer and the evolving role of immunotherapy in this space.

Sara M. Tolaney, MD, MPH, reviews key clinical trial data recently updated in the metastatic HER2+ breast cancer treatment space.

A medical oncologist offers clinical insights on the evolving treatment landscape for patients with HER2+ breast cancer.

A comprehensive overview of the treatment landscape in early-stage breast cancer, with a focus on CDK4/6 and PARP inhibitors.

Sara M. Tolaney, MD, MPH, discusses the evolving role of Ki-67 and circulating tumor DNA as prognostic or predictive biomarkers in breast cancer.

Expert insights on biomarker testing in breast cancer, with a focus on key markers associated with specific subtypes.

Sara M. Tolaney, MD, MPH, an expert breast oncologist, reviews the overall treatment landscape for breast cancer.

Sara M. Tolaney, MD, MPH, discusses how, compared with antibody-drug conjugates, chemotherapy produces low response rates and disease control in the treatment of those with hormone receptor–positive, HER2-negative metastatic breast cancer.

Sara M. Tolaney, MD, MPH, describes the benefit of sacituzumab govitecan for patients with HER2-low metastatic breast cancer seen in the final overall survival analysis of the phase 3 TROPiCS-02 study.

An expert from Dana-Farber Cancer Institute describes which patients hormone receptor-positive, HER2-negative breast cancer will benefit most from treatment with sacituzumab govitecan.

An expert from Dana-Farber Cancer Institute highlights the unmet needs that sacituzumab govitecan meets in the treatment of advanced hormone receptor-positive, HER2-negative breast cancer.

An expert from Dana-Farber Cancer Institute highlights data that supported the FDA’s approval of sacituzumab govitecan for advanced hormone receptor–positive, HER2-negative breast cancer.

An expert from Dana-Farber Cancer Institute discusses what the approval of sacituzumab govitecan means for patients with advanced hormone receptor–positive, HER2-negative breast cancer.

Closing out their review of the HER2+ metastatic breast cancer treatment landscape, expert oncologists look forward to future evolutions in the paradigm.

Panelists center their discussion on the challenges inherent in managing leptomeningeal metastases in patients with HER2+ breast cancer.

Experts share brief insights on novel agents in development for HER2+ breast cancer and consider how they may impact the treatment landscape.

Centering discussion on trastuzumab deruxtecan use in HER2+ metastatic breast cancer, experts elucidate adverse event management and concurrent radiation therapy.

A brief review on how best to use MRI following CNS-directed radiation therapy in patients with HER2+ metastatic breast cancer.

Following review of the final patient scenario, panelists consider later-line treatment options in the setting of multiply relapsed HER2+ metastatic breast cancer.

Comprehensive review of novel combination treatment strategies being explored for patients with HER2+ breast cancer and brain metastases.